Expression of sphingosine kinase gene in the interactions between human gastric carcinoma cell and vascular endothelial cell

doi:10.3748/wjg.v8.i4.602

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 4

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2547)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

308

HTML

1951

Figures (1-2)

149

Tables (1-5)

139

Sum=2547

Aug 15, 2002 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Gastric Cancer

World J Gastroenterol. Aug 15, 2002; 8(4): 602-607
Published online Aug 15, 2002. doi: 10.3748/wjg.v8.i4.602

Table 1 Dose-effect of DMS on HGCC and HVEC for 48 h (n = 8, ¯x ± s)

DMS dose/(μmol/L)	Inhibitory rate of cell proliferation (%)
DMS dose/(μmol/L)	HGCC	HVEC
0 (control)	0	0
1	12.33^b	5.61^b
2	17.53^b	11.11^b
3.5	31.31^b	17.77^b
5	54.68^b	18.41^b
7.5	64.34^b	19.82^b
10	80.68^b	31.02^b
15	89.04^b	65.76^b
20	92.67^b	76.02^b
25	95.91^b	82.32^b
30	97.21^b	83.42^b

^bP < 0.01 vs control.

Table 2 Time-effect of 10 μmol/L DMS on HGCC and HVEC (n = 8, ¯x ± s)

DMS action periods/h	Inhibitory rate of cell proliferation (%)
DMS action periods/h	HGCC	HVEC
0 (control)	0	0
3	9.11^b	5.18^b
6	13.46^b	7.05^b
12	20.18^b	11.12^b
24	41.98^b	19.52^b
48	80.68^b	31.02^b
72	93.55^b	56.44^b

^bP < 0.01 vs control.

Table 3 Different dose-time-effects of CMs of subconfluent and confluent HGCC on HVEC (n = 8, ¯x ± s)

CM volume fraction t/h cell confluent state	A of CM group/A of control group
	100%CM		80%CM		50%CM		30%CM		10%CM
	subconfluent	confluent	subconfluent	confluent	subconfluent	confluent	subconfluent	confluent	subconfluent	confluent
24	2.38 ± 0.01^a	1.29 ± 0.00^a^b	2.70 ± 0.01^a	1.55 ± 0.02^a^b	2.21 ± 0.01^a	1.49 ± 0.02^a^b	2.10 ± 0.03^a	1.44 ± 0.01^a^b	1.92 ± 0.02^a	1.11 ± 0.01^a^b
48	1.60 ± 0.01^a	1.22 ± 0.01^a^b	1.54 ± 0.01^a	1.33 ± 0.02^a^b	1.38 ± 0.02^a	1.23 ± 0.02^a^b	1.37 ± 0.02^a	1.21 ± 0.01^a^b	1.31 ± 0.01^a	1.15 ± 0.02^a^b
72	0.89 ± 0.00	0.85 ± 0.00	0.99 ± 0.01	1.03 ± 0.01	1.07 ± 0.01^a	1.11 ± 0.01^a	1.27 ± 0.01^a	1.01 ± 0.00^b	1.01 ± 0.00	1.15 ± 0.01^a

^aP < 0.05 vs No-CM action group,

^bP < 0.05 vs subconfluent group.

Table 4 Different dose-time-effect of CMs of different preparing periods of confluent HGCC on HVEC (n = 8, ¯x ± s)

CM volume fraction t/h Preparing periods	A of CM group/A of control group
	100%CM		80%CM		50%CM		30%CM		10%CM
	24 hCM	48 hCM	24 hCM	48 hCM	24 hCM	48 hCM	24 hCM	48 hCM	24 hCM	48 hCM
24	1.29 ± 0.01^a	1.38 ± 0.01^a^b	1.55 ± 0.02^a	1.39 ± 0.01^a^b	1.49 ± 0.01^a	1.38 ± 0.01^a^b	1.44 ± 0.02^a	1.30 ± 0.01^a^b	1.11 ± 0.01^a	1.00 ± 0.01^b
48	1.22 ± 0.01^a	1.11 ± 0.02^a^b	1.33 ± 0.01^a	1.14 ± 0.02^a^b	1.23 ± 0.01^a	1.03 ± 0.01^b	1.21 ± 0.01^a	1.03 ± 0.01^b	1.15 ± 0.01^a	1.02 ± 0.01^b
72	0.85 ± 0.01	0.78 ± 0.00	0.99 ± 0.01	0.92 ± 0.00	1.07 ± 0.02^a	1.14 ± 0.01^a^b	1.27 ± 0.01^a	1.20 ± 0.01^a^b	1.15 ± 0.01^a	1.16 ± 0.01^a

^aP < 0.05 vs No-CM action group,

^bP < 0.05 vs preparing for 24 hCM group.

Table 5 Effects of CMs of subconflunt and confluent HVEC on HGCC for 48 h (n = 8, ¯x ± s)

Volume fraction	Inhibitory rate of cell proliferation (%)
Volume fraction	CM of subconfluent HVEC	CM of confluent HVEC
100%CM	52.97 ± 0.01^a	31.62 ± 0.02^a^b
80%CM	54.26 ± 0.01^a	30.46 ± 0.01^a^b
50%CM	23.46 ± 0.01^a	19.00 ± 0.01^a^b
30%CM	21.70 ± 0.00^a	2.13 ± 0.01^b
10%CM	14.36 ± 0.00^a	1.61 ± 0.00^b

^aP < 0.05 vs No-CM action group;

^bP < 0.05 vs subconfluent group.

Citation: Ren J, Dong L, Xu CB, Pan BR. Expression of sphingosine kinase gene in the interactions between human gastric carcinoma cell and vascular endothelial cell. World J Gastroenterol 2002; 8(4): 602-607
URL: https://www.wjgnet.com/1007-9327/full/v8/i4/602.htm
DOI: https://dx.doi.org/10.3748/wjg.v8.i4.602